A New Treatment Option for Advanced Breast Cancer Patients
- The FDA approved giredestrant (Wilserdly) with everolimus for some people with advanced, hormone-fueled breast cancer that has an ESR1 mutation and has grown after earlier hormone therapy. An ESR1 mutation can make breast cancer less responsive to certain hormone therapies.
- In a phase 3 trial, the combination kept the cancer from worsening for a median of 10 months, compared with 5.5 months for older hormone treatments given with everolimus.
- This is not an option for every breast cancer patient. A blood test must find an ESR1 mutation, and the cancer must have progressed on earlier hormone treatment.
- The treatment can cause mouth sores, rash, diarrhea, fatigue and lung inflammation. It can also slow the heart rate.
On Nov. 16, the FDA approved giredestrant (Wilserdly) in combination with everolimus (Afinitor). It is intended for adults with ER-positive, HER2-negative breast cancer (cancer fueled by estrogen that doesn’t have high levels of the HER2 protein) that is locally advanced or has spread to another part of the body. The cancer must also carry an ESR1 mutation and must have returned or worsened during or after previous hormone-based treatment.
Read MoreWhat This Means for Patients
“This approval represents another important step toward more personalized treatment for patients with advanced breast cancer, particularly those whose disease has developed resistance to hormonal therapy,” Dr. Jaime Alberty, Director of the Comprehensive Breast Center at NYC Health + Hospitals/Kings County, tells SurvivorNet.
The main gain is not that this treatment cures metastatic breast cancer. The gain is another chance to control an ESR1-mutated cancer with hormone-directed treatment after an earlier regimen stops working.
For the right patient, that may mean more time before the cancer progresses and another option before moving away from endocrine-based treatment. But the ESR1 test, previous treatments, other tumor mutations, and a patient’s overall health all matter.
“Patients are encouraged to ask their doctor to send genomic testing through a blood test to determine if their cancer has developed an ESR1 mutation, which would make them eligible for the evERA regimen [the combination studied in the evERA trial]. Also, it is important when starting this regimen to use supportive care to prevent side effects; for example, using a preventative steroid mouthwash to prevent mouth sores can be very helpful,” Dr. Mayer says.
Why the ESR1 Mutation Matters
ER-positive means the cancer uses the hormone estrogen as a signal to grow. Hormone treatments work by lowering estrogen or blocking its effect on the cancer.
Over time, though, the cancer can change. An ESR1 mutation alters the estrogen receptor and may allow the cancer to keep growing even when estrogen levels are low. This is one reason a treatment that worked before may eventually stop working.
Giredestrant is designed to block and break down the estrogen receptor, including receptors changed by an ESR1 mutation. Everolimus targets a different growth pathway called mTOR. Using the two drugs together attacks two possible routes the cancer may be using to survive.
The ESR1 mutation is found through molecular testing. The FDA authorized the FoundationOne Liquid CDx blood test as a companion test for this treatment. This type of test looks for small amounts of cancer DNA circulating in the blood.
How Much Did the Treatment Help?
The approval was based on the evERA Breast Cancer trial. Everyone in the study had previously received hormone therapy with a CDK4/6 inhibitor, a common first treatment for this type of advanced breast cancer.
Among the 207 patients whose cancers carried an ESR1 mutation:
- Median progression-free survival was 10 months with giredestrant and everolimus.
- It was 5.5 months with an older hormone treatment and everolimus.
- Tumors shrank in 27% of patients receiving giredestrant, compared with 14% in the comparison group.
Progression-free survival, or PFS, is the length of time patients live without their cancer growing or spreading. “Median” means half of the patients had a longer period of cancer control and half had a shorter one. It does not predict exactly how long an individual patient will benefit.
The study found a 62% reduction in the risk of progression or death during the trial. That does not mean the treatment prevents progression in 62% of patients.
“In the clinical trial, the combination of giredestrant and everolimus nearly doubled the median time before disease progression in patients with ESR1 mutations, offering a meaningful new treatment option,” Dr. Alberty says.
It is also too early to know whether the combination helps people live longer overall. The overall survival results were not mature (not yet complete enough to analyze) when the FDA reviewed the study.
Side Effects Still Matter
This is a chemotherapy-free regimen, but that does not mean it is free of difficult side effects.
The most common problems included mouth sores, rash, tiredness, diarrhea, muscle or joint pain, nausea, and pneumonitis, which is inflammation in the lungs. Blood counts, liver tests, kidney tests and electrolyte levels can also change.
Patients should report a new cough, trouble breathing, fever or worsening mouth sores promptly. Giredestrant can also slow the heart rate. In the trial, this occurred in 3.8% of patients and was asymptomatic, but people with an already slow heart rate or those taking heart-rate-lowering medicines may need closer monitoring.
Questions to Ask Your Doctor:
- Has my cancer been tested for an ESR1 mutation since it began growing again?
- Would a blood-based molecular test be appropriate now?
- How does this combination compare with my other treatment choices?
- What should I expect in terms of prognosis?
- How will you prevent or treat mouth sores?
Learn more about SurvivorNet's rigorous medical review process.

